Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Spartrapon Jan 15, 2021 3:06pm
147 Views
Post# 32308020

RE:RE:Corporate Presentation AWOL

RE:RE:Corporate Presentation AWOL

Yes, quite happy! It looks very straightforward, very well though out to me.

If I had any reservations, that would be about the grouping of Gynecological cancers in a single basket.. Ovarian, endothelial and endometrial.. do they share enough similarities? That looks a bit odd to me intuitively, but maybe it's the case.

Also, something I struggle to perfectly understand is the starting dose of 30 mg/m2 (then doubling to 60, then 100, 150, 210 and 280 according to fibonacci progression)  . That seems a bit lowish, intuitively speaking again.

The reported MTD of docetaxel is not easy to find, but I gathered for heavily pretreated pts it's around 125 mg/m2. TH1902 is made of a peptide and of 2 molecules of docetaxel, so without knowing exactly the molecular weight of the peptide, I'd guess it represents more or less 50% of the weight of th1902.

So the starting dose would be equivalent to ~15 mg/m2 of Docetaxel, and subsequent doses be like 30, 50, 75 [the recommended Docetaxel dose], 105 and then 140 of equivalent docetaxel.

With pre-clinicals hinting at TH-1902's MTD being 3 times the Docetaxel MTD (IIRC), it seems to me we are on the lowish/safeish side and may probably not reach a DLT.

I'm not sure if this is a problem at this stage. Maybe also when they say "dose-doubling will be done for the first 2 dose levels", they mean the first two dose levels not including the starting dose. That would therefore imply a much wider span (30, 60, 120 for doubling, 200, 300, 420, 540 for Fibonacci) and would be perfect...

qwerty22 wrote:

You happy with the cancer protocol?

 

Spartrap wrote:

 


OK, it's rant time for me finally.. I guess I'm always a bit out of schedule:

What kind of company removes its Corporate Presentation, the essential tool for gathering first insights, right before and during a financing?! It's been AWOL and replaced by a placeholder since January 8 according to a Scarlet post.

Seriously, 8 days!

Where exactly, may I ask, are new investors supposed to gather informations about their new investment? That is completely unacceptable and amateurish!

And by the way, this resonates with the out-of-fashion, unattractive website, and e-mail alerts that only arrive one timeout of 3 (!!!). I agree with many here, to say that lots of changes are urgently needed in the communication department.





<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse